August 1st 2025
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
Advancing Innovation in Cancer Care: Bringing the Next Wave of Oncology Products to Market
July 8th 2025While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.
2025 Pharm Exec Top 50 Companies
June 20th 2025With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales producers, its 25th, points to the importance of organizations doubling down on what they do best while seizing new opportunities to innovate.
Guiding Pharma Through Geopolitical Uncertainty: Q&A with the Federated Healthcare Advisory Panel
May 27th 2025In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.
Applying Porter’s Five Forces to Portfolio Management in Pharmaceutical R&D: A Strategic Roadmap
March 17th 2025The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage.